S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
Log in

NASDAQ:IRWDIronwood Pharmaceuticals Price Target & Analyst Ratings

$10.09
+0.45 (+4.67 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.72
Now: $10.09
$10.45
50-Day Range
$9.14
MA: $9.89
$10.60
52-Week Range
$7.91
Now: $10.09
$14.10
Volume1.86 million shs
Average Volume2.09 million shs
Market Capitalization$1.61 billion
P/E Ratio19.04
Dividend YieldN/A
Beta1.37

Analyst Ratings

Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Ironwood Pharmaceuticals in the last 12 months. Their average twelve-month price target is $12.17, suggesting that the stock has a possible upside of 20.58%. The high price target for IRWD is $15.00 and the low price target for IRWD is $10.00. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.292.172.33
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.17$12.29$12.50$14.88
Price Target Upside: 20.58% upside31.96% upside23.03% upside20.15% upside

Ironwood Pharmaceuticals (NASDAQ:IRWD) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ironwood Pharmaceuticals (NASDAQ:IRWD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/3/2020Northland SecuritiesReiterated RatingBuyHigh
7/15/2020Morgan StanleyLower Price TargetEqual Weight$11.00 ➝ $10.00Low
6/1/2020Credit Suisse GroupLower Price TargetNeutral$12.00 ➝ $11.00Low
5/11/2020HC WainwrightLower Price TargetNeutral$13.00 ➝ $11.00High
4/30/2020Wells Fargo & CoLower Price TargetOverweight$16.00 ➝ $15.00Medium
9/13/2019CowenSet Price TargetHold$12.00Low
7/31/2019WedbushBoost Price TargetNeutral$11.00 ➝ $12.00High
5/2/2019MizuhoSet Price TargetBuy$20.00High
2/26/2019Wood & CompanyInitiated CoverageBuyMedium
2/25/2019GMP SecuritiesUpgradeSell ➝ Neutral$11.50 ➝ $14.00High
2/14/2019BTIG ResearchSet Price TargetBuy$19.00High
1/24/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$11.00 ➝ $13.00Low
5/2/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $20.00Low
4/19/2018Berenberg BankInitiated CoverageBuy$25.00Medium
1/5/2018Bank of AmericaDowngradeBuy ➝ Underperform$20.00 ➝ $15.00High
(Data available from 8/6/2018 forward)
This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.